HOME >> MEDICINE >> NEWS
Synthetic marijuana compound reduces agitation, improves appetite in Alzheimer's patients

Chicago, Ill. and Neptune, N.J. (August 20, 2003) Study results suggest dronabinol, a synthetic version of THC, the active ingredient in Cannabis sativa L (marijuana), may reduce agitation and lead to weight gain in patients with Alzheimer's disease, according to data presented today at the annual meeting of the International Psychogeriatric Association.

"Our research suggests dronabinol may reduce agitation and improve appetite in patients with Alzheimer's disease, when traditional therapies are not successful," said Joshua Shua-Haim, M.D., lead investigator in the study and medical director of the Meridian Institute for Aging, a continuum of senior health programs and services in Central New Jersey affiliated with Meridian Health System. "In the study, dronabinol appeared to be safe and effective for these patients. The results point to a promising direction for future research."

Dronabinol, marketed under the trade name Marinol, is synthetic delta-9-tetrahydrocannabinol (delta-9-THC). Delta-9-THC also is a naturally occurring component of Cannabis sativa L (marijuana). Dronabinol is the only cannabinoid approved by the U.S. Food and Drug Administration (FDA) and is indicated for the treatment of anorexia in patients with HIV/AIDS and for the treatment of nausea and vomiting associated with cancer chemotherapy.

An estimated four million Americans have Alzheimer's disease and the number will grow to 14 million by 2050, according to the Alzheimer's Association. In addition to memory loss, patients often experience agitation, loss of body weight, depression and restlessness.

Agitation is the most frequently encountered type of behavioral disturbance associated with Alzheimer's disease and affects an estimated 75 percent of people with the disease. Weight loss, a common problem in patients with Alzheimer's disease, is a predictive factor of mortality. Weight loss may derive from the deterioration of patients' cognitive abiliti
'"/>

Contact: Michael Valentino
mvalentino@meridianhealth.com
732-751-7538
Meridian Health System
20-Aug-2003


Page: 1 2

Related medicine news :

1. Synthetic progestin damages, estrogen protects blood vessels in animal model
2. Synthetic marijuana reduces agitation in patients with Alzheimers
3. Synthetic rubber kills germs on contact
4. Views Of Tamoxifen And Synthetic Estrogen In Action Provide Clues For Designing Better Drugs
5. UCSF Study In Rats Suggests Synthetic Drug Mimicking Marijuana Might Be Used To Treat Pain
6. "Green Chemistry" Cleans Up Environment And Renders Synthetic Drugs
7. Synthetic Detergent Found To Fight Multi-Drug Resistance
8. Yale to study marijuana, ecstasy and teen cognitive deficits
9. Adult marijuana abuse, dependence increased during 1990s
10. Increase in prevalence of marijuana abuse and dependence
11. Rare risk: Adolescent binging on marijuana linked to stroke

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/5/2020)... LEXINGTON, Ky. (PRWEB) , ... August 05, 2020 , ... ... App to help everyone gain access to essential COVID-19 information. Know NOW!, which ... various sources of COVID-19 updates and unify them in one easy-to-use mobile application. , ...
(Date:8/5/2020)... ... August 04, 2020 , ... Total Spectrum, ... Spectrum Disorder (ASD) in Wisconsin, is delighted to announce the grand opening of ... of their newest center, Total Spectrum now proudly serves ten different locations across ...
(Date:8/5/2020)... ... ... Today, Power to Decide’s One Key Question was recognized by ... Best Practice Award. The One Key Question program is a transformative tool that starts ... a child. One Key Question is used by thousands of health care, social service ...
(Date:8/3/2020)... Ariz. (PRWEB) , ... August 03, 2020 , ... ... announced today the launch of its newest product, CoverageCoach. The site provides a ... compare, and purchase insurance products. The company sees CoverageCoach as an important expansion ...
(Date:8/3/2020)... ... August 03, 2020 , ... Actuate Therapeutics, Inc. ... with first-line advanced pancreatic cancer in a phase 2 study of 9-ING-41, as ... EudraCT#:2018-003739-32). 9-ING-41 is Actuate’s proprietary small molecule glycogen synthase kinase-3 beta (GSK-3ß) ...
Breaking Medicine News(10 mins):
(Date:8/9/2020)... (PRWEB) , ... August 09, 2020 , ... ... focused on sustainable results, today announced that Lydia C. Alexander, MD, has joined ... obesity medicine specialist, Dr. Alexander will play a vital role in expanding Enara ...
(Date:8/7/2020)... (PRWEB) , ... August 07, 2020 , ... ... published a literature review showing how sleep is a mechanism connecting social inequalities ... at the CDC’s survey of close to 444,000 Americans that draws direct relationships ...
(Date:8/7/2020)... ... August 07, 2020 , ... Aquila Recovery, a DC ... intensive outpatient programs are and who they are ideal for. , Thousands ... to intensive outpatient programs provided by addiction recovery centers. An intensive outpatient program, ...
Breaking Medicine Technology:
Cached News: